Generation of an esterolytic and kinin-forming kallikrein-α2-macroglobulin complex in human serum by treatment with acetone

  • W. Vogt
  • B. Dugal
Article

Summary

Kinin-forming and esterolytic activity in human citrate plasma has been activated by treatment of the plasma with acetone. By far most of the esterolytic activity if not all of it was recovered in an α2-macroglobulin (α2M) kallikrein complex (SI) which was characterized and purified by chromatography. Little if any esterolytic activity was present which could be ascribed to free plasma kallikrein. The α2M-kallikrein complex had kinin-releasing activity though much less than free plasma kallikrein, relative to esterolytic potency. This explains that a considerable fraction of the kinin-forming potential of acetone-activated plasma resides in free plasma kallikrein although it represents only a very small portion of the total kallikrein store. Like free plasma kallikrein the α2M complex releases kinin from LMW-kininogen less efficiently than from HMW, in systems of purified components. In whole plasma, the efficiencies change: whereas plasma kallikrein is rapidly inactivated by endogenous inhibitors, the α2M complex is protected from further inactivation and capable of releasing kinin continuously if slowly, attacking also LMW-kininogen after HMW-kininogen has been consumed by free kallikrein. While the α2M-complex in this respect differs functionally from free plasma kallikrein and explains earlier observations suggesting the presence of two kininogenases, it seems doubtful now that two truly different kininogenases exist in human plasma.

The results suggest that acetone predominantly inactivates full inhibitors of kallikrein such as C1INH whereas α2M is somewhat more resistant and (pre-)-kallikrein even more. Depending on the time and temperature of acetone treatment one obtains more or less total kallikrein and varying proportions of free to bound enzyme. It is likely that acetone does not truly trigger an activation of prekallikrein but supports spontaneous activation by slowing down the control of the feedback reinforcement of this activation, by damaging inhibitors.

Key words

Kallikrein α2 macroglobulin Plasma Esterase inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong, D., Mills, G. L., Sicuteri, F.: Physiological influence on the liberation of human plasma kinin at low temperature. In: Hypotensive peptides. (E. G. Erdös, N. Back, and F. Sicuteri, eds.), pp. 185–197. New York: Springer 1966Google Scholar
  2. Bagdasarian, A., Lahiri, B., Talamo, R. C., Wong, P., Colman, R. W.: Immunochemical studies on plasma kallikrein. J. clin. Invest.54, 1444–1454 (1974)Google Scholar
  3. Briseid, K., Arntzen, F. C., Dyrud, O. K.: Studies on the release of kinin by acetone in human plasma. Acta pharmacol. (Kbh.)26, 402–412 (1968)Google Scholar
  4. Cochrane, C. G., Revak, S. D., Wuepper, K. D.: Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J. exp. Med.138, 1564–1583 (1973)Google Scholar
  5. Dyce, B., Wong, T., Adham, N., Mehl, J., Haverback, B.: Human plasma kallikrein esterase associated with the alpha-2-macroglobulin binding protein. Clin. Res.15, 101 (1967)Google Scholar
  6. Fritz, H., Brey, B., Schmal, A., Werle, E.: Zur Identität des Progressiv-Antikallikreins mit α1-Antitrypsin aus Humanserum. Hoppe-Seylers Z. physiol. Chem.350, 1551–1555 (1969)Google Scholar
  7. Fritz, H., Wunderer, G., Dittmann, B.: Zur Isolierung von Schweine-und Human-Serumkallikrein durch Affinitätschromatographie. Hoppe-Seylers Z. physiol. Chem.353, 893–900 (1972)Google Scholar
  8. Ganrot, P. O.: Inhibition of plasmin activity by α2-macroglobulin. Clin. chim. Acta16, 328–330 (1967)Google Scholar
  9. Gigli, I., Mason, J. W., Colman, R. W., Austen, K. F.: Interaction of plasma kallikrein with C1 inhibitor. J. Immunol.104, 574–581 (1970)Google Scholar
  10. Habal, F. M., Movat, H. Z.: Kininogens of human plasma. Res. Comm. chem. Path. Pharmacol.4, 477–486 (1972)Google Scholar
  11. Habermann, E.: Inhibitors of kallikrein and other proteinases from animal blood. Ann. N. Y. Acad. Sci.146, 479–490 (1968)Google Scholar
  12. Harpel, P. C.: Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J. exp. Med.132, 329–352 (1970)Google Scholar
  13. Heimburger, N., Haupt, H., Schwick, H. G.: Proteinase inhibitors of human plasma. Proceedings of the International Research Conference on proteinase inhibitors, Munich, Nov. 1970, pp. 1–22. Berlin-New York: W. de Gruyter 1971Google Scholar
  14. Kagen, L. J., Becker, E. L.: Inhibition of permeability globulins by C'1-esterase inhibitor. Fed. Proc.22, 613 (1963)Google Scholar
  15. Kraut, H., Frey, E. K., Werle, E.: Über den Nachweis und das Vorkommen des Kallikreins im Blut. VIII. Mitteilung über Kallikrein. Hoppe-Seylers Z. physiol. Chem.222, 73–99 (1933)Google Scholar
  16. Laake, K., Gjonnaess, H., Fagerhol, M. K.: Components of the kallikrein-kinin system and the spontaneous cold activation of factor VII in human plasma. Acta pharmacol. (Kbh.)33, 229–240 (1973)Google Scholar
  17. Margolis, J.: Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J. Physiol. (Lond.)144, 1–22 (1958)Google Scholar
  18. McConnell, D. J.: Inhibitors of kallikrein in human plasma. J. clin. Invest.51, 1611–1623 (1972)Google Scholar
  19. Mehl, J. W., Park, M. Y., O'Connell, W.: Separation of trypsin inhibitors of human plasma on DEAE cellulose. Proc. Soc. exp. Biol. (N. Y.)122, 203–210 (1966)Google Scholar
  20. Moriya, H., Yamazaki, K., Fukushima, H.: Biochemical studies on kallikreins and their related substances. III. Preliminary experiment of studies on human plasma kallikrein. J. Biochem.58, 315–319 (1965)Google Scholar
  21. Razafimahaleo, E., Bourrillon, R.: Études sur la structure de l'α2 macroglobuline humaine. I. Préparation de l'α2 macroglobuline humaine. Biochim. biophys. Acta (Amst.)154, 397–404 (1968)Google Scholar
  22. Seidel, G.: Two functionally different kininogens in human plasma. Agents and Actions3, 12–19 (1973)Google Scholar
  23. Trautschold, I., Werle, E., Schweitzer, G.: Kallikrein. In: Methoden der enzymatischen Analyse, 2nd Edit. (H. U. Bergmeyer, ed.), pp. 1011–1020. Weinheim: Verlag Chemie 1970Google Scholar
  24. Vogt, W.: Demonstration of the presence of two separate kinin-forming systems in human and other plasma. In: Hypotensive peptides. (E. G. Erdös, N. Back, and F. Sicuteri, eds.), pp. 185–197. New York: Springer 1966Google Scholar
  25. Vogt, W., Garbe, G., Schmidt, G.: Untersuchungen zur Existenz zweier verschiedener kininbildender Systeme in menschlichem Plasma. Naunyn-Schmiedebergs. Arch. Pharmak. exp. Path.256, 127–138 (1967)Google Scholar
  26. Webster, M. E., Pierce, J. V.: Studies on plasma kallikrein and its relationship to plasmin. J. Pharmacol. exp. Ther.130, 484–491 (1960)Google Scholar
  27. Webster, M. E., Pierce, J. V.: Action of the kallikreins on synthetic ester substrates. Proc. Soc. exp. Biol. (N. Y.)107, 186–191 (1961)Google Scholar
  28. Weiss, A. S., Gallin, J. I., Kaplan, A. P.: Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. clin. Invest.53, 622–633 (1974)Google Scholar
  29. Wendel, U., Vogt, W., Seidel, G.: Purification and some properties of a kininogenase from human plasma activated by surface contact. Hoppe-Seylers Z. physiol. Chem.353, 1591–1606 (1972)Google Scholar
  30. Wuepper, K.: Prekallikrein deficiency in man. J. exp. Med.138, 1345–1355 (1973)Google Scholar
  31. Wuepper, K. D., Cochrane, C. G.: Plasma prekallikrein: isolation, characterization, and mechanism of activation. J. exp. Med.135, 1–20 (1972)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • W. Vogt
    • 1
  • B. Dugal
    • 1
  1. 1.Abteilung Biochemische PharmakologieMax-Planck-Institut für experimentelle MedizinGöttingenFederal Republic of Germany

Personalised recommendations